首页> 外文期刊>Nuclearmedicine >Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin: Diagnostic implication of TSH-stimulated antithyroglobulin antibody [überwachung bei Patienten mit differenziertem schilddrüsenkarzinom und negativem serum- thyreoglobulin: Bedeutung von thyreoglobulin-antik?rpern unter tsh-stimulation für die diagnostik]
【24h】

Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin: Diagnostic implication of TSH-stimulated antithyroglobulin antibody [überwachung bei Patienten mit differenziertem schilddrüsenkarzinom und negativem serum- thyreoglobulin: Bedeutung von thyreoglobulin-antik?rpern unter tsh-stimulation für die diagnostik]

机译:监测血清甲状腺球蛋白阴性的分化型甲状腺癌患者:TSH刺激的抗甲状腺球蛋白抗体的诊断意义

获取原文
获取原文并翻译 | 示例
       

摘要

Aim: Serum antithyroglobulin antibody (TgAb) has been reported as a surrogate marker for differentiated thyroid cancer (DTC) in some conditions. We investigated changes in serum TgAb levels after stimulation with thyroidstimulating hormone (TSH) and the clinical implications for monitoring DTC. Patients, methods: We retrospectively enrolled 53 DTC patients who had undergone total thyroidectomy and were negative for serum Tg and positive for TgAb. Patients underwent highdose radioactive iodine treatment, and serum TgAb was measured before (TgAbBAS) and after TSH stimulation (TgAbSTIM). TgAb was followed up 6 to 12 months later (TgAbF/U). The change in TgAb after TSH stimulation (ΔTgAb- STIM) was calculated as a percentage of the baseline level. Patient disease status was classified into no residual disease (ND) and residual or recurred disease (RD) by follow-up imaging studies and pathologic data. The characteristics and diagnostic value of serum TgAb levels and ΔTgAbSTIM were investigated with respect to disease status. Results: 38 patients were in the ND group and 15 were in the RD group. TgAbBAS, TgAbSTIM and TgAbF/U were significantly higher in the RD compared to the ND group (p = 0.0008, 0.0002, and 0.0001, respectively). ΔTgAbSTIM was also significantly higher in the RD group (p = 0.0009). In the patients who presented with obviously high (≥ 50%) or low ( -50%) ΔTgAbSTIM, the proportions in the RD group were markedly different at 100% and 7%, respectively. ΔTgAbSTIM had significant diagnostic value for RD (p 0.001). Conclusion: The change in serum TgAb level after TSH stimulation is different between the RD and ND groups, and thus, it may be used as a surrogate diagnostic marker for DTC when the serum Tg is negative and TgAb is positive.
机译:目的:在某些情况下,血清抗甲状腺球蛋白抗体(TgAb)已被报道作为分化型甲状腺癌(DTC)的替代标志物。我们调查了甲状腺刺激激素(TSH)刺激后血清TgAb水平的变化以及监测DTC的临床意义。患者,方法:我们回顾性研究了53例接受全甲状腺切除术且血清Tg阴性和TgAb阳性的DTC患者。患者接受高剂量放射性碘治疗,并在促甲状腺激素刺激前和促甲状腺激素刺激后测量血清TgAb。对TgAb进行了6到12个月的随访(TgAbF / U)。 TSH刺激后TgAb的变化(ΔTgAb-STIM)计算为基线水平的百分比。通过随访影像学研究和病理学数据,将患者的疾病状况分为无残留疾病(ND)和残留或复发性疾病(RD)。就疾病状况调查了血清TgAb水平和ΔTgAbSTIM的特征和诊断价值。结果:ND组38例,RD组15例。与ND组相比,RD中的TgAbBAS,TgAbSTIM和TgAbF / U显着更高(分别为p = 0.0008、0.0002和<0.0001)。 RD组的ΔTgAbSTIM也显着较高(p = 0.0009)。在出现明显高(≥50%)或低(<-50%)ΔTgAbSTIM的患者中,RD组的比例分别显着不同,分别为100%和7%。 ΔTgAbSTIM对RD具有重要的诊断价值(p <0.001)。结论:RD和ND组TSH刺激后血清TgAb水平的变化是不同的,因此,当血清Tg为阴性而TgAb为阳性时,可作为DTC的替代诊断标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号